Pfizer Inc. (NYSE:PFE) Shares Sold by AE Wealth Management LLC

AE Wealth Management LLC reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 976,817 shares of the biopharmaceutical company's stock after selling 80,691 shares during the quarter. AE Wealth Management LLC's holdings in Pfizer were worth $24,753,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter valued at $27,000. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. purchased a new position in shares of Pfizer during the 1st quarter worth $28,000. Bernard Wealth Management Corp. purchased a new position in shares of Pfizer during the 4th quarter worth $30,000. Finally, Horizon Financial Services LLC purchased a new position in shares of Pfizer during the 1st quarter worth $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Morgan Stanley increased their target price on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 30th. Citigroup increased their target price on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Bank of America increased their target price on Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group increased their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.

Pfizer Price Performance

PFE stock traded down $0.57 during midday trading on Friday, hitting $24.79. 35,628,980 shares of the stock were exchanged, compared to its average volume of 38,205,096. The stock's 50-day moving average price is $24.30 and its 200-day moving average price is $24.68. The stock has a market cap of $140.91 billion, a price-to-earnings ratio of 17.96, a PEG ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. Pfizer's revenue was down 7.8% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.94%. Pfizer's dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.